CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
44 hedge funds and large institutions have $18.9M invested in CASI Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 10 closing their positions.
0.33% less ownership
Funds ownership: 2% → 1.67% (-0.33%)
14% less funds holding
Funds holding: 51 → 44 (-7)
16% less capital invested
Capital invested by funds: $22.4M → $18.9M (-$3.48M)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
64% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 14
Top Buyers
| 1 |
WSC
Wellington Shields & Co
New York
|
+$245K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$106K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$76.3K |
| 4 |
Citigroup
New York
|
+$57.4K |
| 5 |
VF
Virtu Financial
New York
|
+$25.1K |
Top Sellers
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.34M |
| 2 |
Renaissance Technologies
New York
|
-$1.02M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$620K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$241K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$214K |
CASI Hedge Fund Activity: Q1 2022 in Review
44 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2022, worth a combined $18.9M — down 16% from $22.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CASI and 4 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 5 added.
The largest buyer was Wellington Shields & Co, adding an estimated $245K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $1.34M sold.
- 44 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2022, down from 51 in Q4 2021.
- Funds reported $18.9M of CASI Pharmaceuticals stock for Q1 2022, down 16% quarter-over-quarter.
- 4 funds opened new CASI Pharmaceuticals positions in Q1 2022 and 10 closed out, a net change of -6 holders.
- The largest CASI Pharmaceuticals buyer in Q1 2022 was Wellington Shields & Co, an estimated $245K added.
- The largest CASI Pharmaceuticals seller in Q1 2022 was Jacobs Levy Equity Management, an estimated $1.34M sold.
Based on aggregated 13F filings for Q1 2022.